HCM
NVNO

Heights Capital Management’s enVVeno Medical NVNO Stock Holding History

Heights Capital Management’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,042
Closed -$475K – 156
2024
Q3 		$475K Buy
+4,042
New +$743K 0.35% 38

Other funds holding NVNO

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Heights Capital Management's NVNO Position: Q4 2024 in Review

Heights Capital Management sold out of enVVeno Medical (NVNO) in Q4 2024, closing a stake of 4,042 shares — an estimated $475K sold.

Heights Capital Management first reported a position in NVNO in Q3 2024 and held it in 1 quarter. The position peaked at $475K in Q3 2024. 34 funds tracked by Wall St. Rank hold NVNO as of Q4 2024.

  • Heights Capital Management reported no remaining enVVeno Medical position as of Q4 2024 after selling out during the quarter.
  • Heights Capital Management sold 4,042 enVVeno Medical shares in Q4 2024, an estimated $475K.
  • Heights Capital Management first reported a position in enVVeno Medical in Q3 2024 and held it in 1 quarter.
  • Heights Capital Management's enVVeno Medical position peaked at $475K in Q3 2024.
  • 34 funds tracked by Wall St. Rank held enVVeno Medical as of Q4 2024.

Based on Heights Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.